ArticleMolecular psychiatry2004
A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses.
Article in Molecular psychiatry, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 68 citations in OpenAlex.
- Chromosomal regions strongly associated with waist circumference and body mass index in metabolic syndrome in a family-based study.Scientific reports · 2021Trial
- Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.Molecular psychiatry · 2007Trial
- Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.Behavioral sciences (Basel, Switzerland) · 2021Review
- TOX and ADIPOQ Gene Polymorphisms Are Associated with Antipsychotic-Induced Weight Gain in Han Chinese.Scientific reports · 2017Article
- Genome-Wide Association Study Suggested the PTPRD Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications.Schizophrenia bulletin · 2016Article
- Genome-wide association study identifies African-ancestry specific variants for metabolic syndrome.Molecular genetics and metabolism · 2015Article
- Article
- Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2012Article
- Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.Molecular psychiatry · 2012Review
- Group 1B phospholipase A₂ deficiency protects against diet-induced hyperlipidemia in mice.Journal of lipid research · 2011Article
- Review
- Genome-wide linkage and peak-wide association study of obesity-related quantitative traits in Caribbean Hispanics.Human genetics · 2011Article
- Genetic variance in the spinocerebellar ataxia type 2 (ATXN2) gene in children with severe early onset obesity.PloS one · 2009Article
- Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats.Psychopharmacology · 2009Article
- Can body mass index help predict outcome in patients with bipolar disorder?Bipolar disorders · 2009Article
- [Genetics of weight gain associated with antipsychotic medications].Der Nervenarzt · 2009Review
- Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.Molecular psychiatry · 2007Review
- A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function.Molecular psychiatry · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antipsychotics can induce in schizophrenic (SZ) and bipolar disorder (BP) patients serious body weight changes that increase risk for noncompliance to medication, and risk for cardiovascular diseases and diabetes. A genetic origin for this susceptibility to weight changes has been hypothesized because only a proportion of treated patients are affected, the degree of affection differing also in rates and magnitudes. In a first genome scan on obesity under antipsychotics in SZ and BP, we analyzed 21 multigenerational kindreds (508 family members) including several patients treated for a minimum of 3 years mainly with haloperidol or chlopromazine. Obesity was defined from medical files and was shown to be 2.5 times more frequent in patients treated with antipsychotics than in untreated family members (30 vs 12%). The nine pedigrees that showed at least two occurrences of obesity under antipsychotics were submitted to model-based linkage analyses. We observed a suggestive linkage with a multipoint Lod score (MLS) of 2.74 at 12q24. This linkage finding vanished when we used as phenotypes, obesity unrelated to antipsychotics, and when we used SZ or BP. This suggests that this positive linkage result with obesity is specific to the use of antipsychotics. A potential candidate gene for this linkage is the pro-melanin-concentrating hormone (PMCH) gene located at less then 1 cM of the linkage. PMCH encodes a neuropeptide involved in the control of food intake, energy expenditure, and in anxiety/depression. This first genome scan targeting the obesity side effect of antipsychotics identified 12q24 as a susceptibility region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.